Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001650664-24-000097
Filing Date
2024-08-07
Accepted
2024-08-07 16:11:10
Documents
55
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q edit-20240630.htm   iXBRL 10-Q 845898
2 EX-31.1 edit-20240630xex311.htm EX-31.1 9646
3 EX-31.2 edit-20240630xex312.htm EX-31.2 9619
4 EX-32.1 edit-20240630xex321.htm EX-32.1 6469
  Complete submission text file 0001650664-24-000097.txt   4375571

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT edit-20240630.xsd EX-101.SCH 25577
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT edit-20240630_cal.xml EX-101.CAL 50024
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT edit-20240630_def.xml EX-101.DEF 111693
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT edit-20240630_lab.xml EX-101.LAB 467805
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT edit-20240630_pre.xml EX-101.PRE 291300
57 EXTRACTED XBRL INSTANCE DOCUMENT edit-20240630_htm.xml XML 521425
Mailing Address 11 HURLEY ST. CAMBRIDGE MA 02141
Business Address 11 HURLEY ST. CAMBRIDGE MA 02141 617-401-9000
Editas Medicine, Inc. (Filer) CIK: 0001650664 (see all company filings)

EIN.: 464097528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37687 | Film No.: 241183853
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)